Project 3: Defining adaptive immune interactions that shape Clostridioides difficile infection
Project 3: Defining adaptive immune interactions that shape Clostridioides difficile infection
批准号:
10625579
负责人:
Michael C. Abt
金额:
$34.82万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-03-01 至 2028-02-29
关键词:
AcuteAgeAnimal ModelAnimalsAntibodiesAntibody ResponseAutomobile DrivingB-LymphocytesBindingCD4 Positive T LymphocytesCell Differentiation processCell Surface ProteinsCellsCharacteristicsChildhoodChronic PhaseClinicalClostridium difficileComplementDNADataDefectDiseaseElderlyEngineeringFecesFeedbackFiltrationFlow CytometryGenerationsGenetic TranscriptionGoalsHelper-Inducer T-LymphocyteHumanImmuneImmune EvasionImmune TargetingImmune responseImmune systemImmunityImmunocompetentImmunodeficient MouseImmunologic MemoryImmunoprecipitationImpairmentIn SituIn VitroInfectionIntestinal MucosaIntestinesLarge IntestineMass Spectrum AnalysisMemory B-LymphocyteMessenger RNAMicroscopyMucosal ImmunityMucous body substanceMusNatural ImmunityPathway interactionsPatientsPhysiologyPopulationPrimary InfectionRNA vaccineRag1 MouseRecurrenceReportingResolutionRiskSamplingSerumSeverity of illnessShapesSterilitySystemToxinVaccinatedVaccine Clinical TrialVaccine DesignVaccinesVirulence FactorsVisualizationadaptive immune responseadaptive immunityage relatedageddraining lymph nodeexperiencefecal transplantationhigh dimensionalityhigh riskhigh risk populationin vivometagenomic sequencingmicrobialoutcome disparitiespathogenpatient populationpressurepreventprimary endpointrecurrent infectionresponsesuccesstranscriptometranscriptome sequencingtransmission processunvaccinatedvaccine candidatevaccine developmentvaccine responsevaccine trialvaccine-induced immunityyoung adult
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY: PROJECT 3 - IMMUNOLOGY
The quality of the host immune response to Clostridioides difficile infection is one of the strongest predictors of
disease severity. Despite the protective capacity of the host immune response, the immune parameters that
promote immunity remain poorly understood. Approximately 25-35% of patients that recover from primary C.
difficile infection will experience a recurrence episode indicating the host often fails to develop natural immunity
following primary infection. Further, multiple vaccine trails have not met primary endpoint of reducing
occurrence of infection despite the vaccine candidates eliciting robust antibody responses against C. difficile
toxins, the primary virulence factors driving disease. A limited mechanistic understanding of why the
natural immune response to infection often does not promote immunity represents a critical roadblock
toward the goal of developing a vaccine that will elicit lasting protective immunity in high-risk
populations. This project will systematically evaluate the natural immune response to C. difficile infection
using both patient sample and a murine infection system. In aim 1 we will compare the capacity of the systemic
and intestinal mucosal antibodies elicited following infection to detect and bind to C difficile residing in the
intestinal lumen. Successful generation of an antibody response that targets C. difficile in the intestinal tract is
dependent on a coordinated C. difficile-specific CD4+ T and B cell response in the intestine and associated
draining lymph nodes and is the focus of studies proposed in aim 2. Last, in aim 3 we will investigate the in
vivo biogeography and transcriptome of C. difficile in the presence of adaptive immune pressure to identify
immune evasion mechanisms employed by C. difficile to promote persistence and transmission. The result of
all three aims will feedback into Project 1 (Vaccine Development) to inform mRNA vaccine studies by
providing a template how vaccine-induced immunity can be shaped to limit disease, prevent colonization, and
recurrence of C. difficile.
1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantation
-
批准号:10549862
-
项目类别:
-
资助金额:$46.89万
-
财政年份:2021
-
负责人:Michael C. Abt
-
依托单位:
Immune regulation of the transcriptional and spatial profile of Clostridioides difficile
-
批准号:10448396
-
项目类别:
-
资助金额:$20.31万
-
财政年份:2021
-
负责人:Michael C. Abt
-
依托单位:
Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantation
-
批准号:10343845
-
项目类别:
-
资助金额:$47.62万
-
财政年份:2021
-
负责人:Michael C. Abt
-
依托单位:
Immune regulation of the transcriptional and spatial profile of Clostridioides difficile
-
批准号:10288376
-
项目类别:
-
资助金额:$24.38万
-
财政年份:2021
-
负责人:Michael C. Abt
-
依托单位:
Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantation
-
批准号:10185169
-
项目类别:
-
资助金额:$47.43万
-
财政年份:2021
-
负责人:Michael C. Abt
-
依托单位:
Treating chronic viral infection by epigenetic reprogramming of exhausted CD8 T cells
-
批准号:10242714
-
项目类别:
-
资助金额:$52.96万
-
财政年份:2017
-
负责人:Michael C. Abt
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: